Site is in test mode. We will go live shortly

(Germany) +49-(0)-25929626604 | (India) +91-79-48908478

mobile-logo

Articles

Food and Drugs (Amendment) Act 2016 New! Recently Updated

MedicinesHerbal Cosmetic Nutra | Belize

AN ACT to amend the Food a d Drugs Act, Chapter 291 of the Substantive Laws of Belize, Revised Edition 2011, to make provision empowering the making of regulations to empower to the establishment of a drug registry as well as generally to give effect to the provisions of the Act, to make Further provisions regarding the labelling of food or drug products; and
to provide for matter connected therewith or incidental thereto.

Read More Favorite

Food and Drugs (Registration, Licensing, Inspection) 2017 New! Recently Updated

MedicinesHerbal Cosmetic Nutra | Belize

REGULATIONS made by the Minister responsible for health in the exercise of the powers conferred upon him by
section 55 of the Food and Drugs Act, Chapter 291 of the Substantive Laws of Belize, Revised Edition 2011 and all other powers thereunto him enabling.

This guideline describes the following points;

  • PART I Preliminary
  • PART 2 Registration and Licensing of Drugs
  • PART 3 Facility Licence
  • PART 4 Miscellaneous

 

Read More Favorite

Guideline on Active Substance Master File Procedure  

Medicines | European Union

The main objective of the Active Substance Master File (ASMF) procedure, formerly known as the European Drug Master File (EDMF) procedure, is to allow valuable confidential intellectual property or ‘know-how’ of the manufacturer of the active substance (ASM) to be protected, while at the same time allowing the Applicant or Marketing Authorisation (MA) holder to take full responsibility for the medicinal product and the quality and quality control of the active substance.

This Guideline is intended to assist Applicants/MA holders in the compilation of the active substance section of their dossiers for a Marketing Authorisation Application (MAA) or a Marketing Authorisation Variation (MAV) of a medicinal product. It is also intended to help ASMF holders in the compilation of their ASMFs.

This guideline also contains the following points;

  1. Content of the Active Substance Master File
  2. Use of the Active Substance Master File Procedure
  3. Content of the MA-dossier when the Active Substance Master File Procedure is used
  4. Changes and updates to the Active Substance Master File
Read More Favorite

Guideline on Pharmaceutical Development of Medicines for Paediatric Use  

Medicines | European Union

The principles of this guideline should be considered during the pharmaceutical development of all paediatric medicines as proposed in marketing-authorisation applications (MAAs) or applications to extend or vary marketing authorisations to the paediatric population (MAVs). Depending on the phase of the development, the principles of this guideline should also be considered for the purpose of the paediatric investigation plan (PIP) applications. While taking into account that the regulation of medicinal products must be fundamentally aimed at safeguarding public health, it is important to realize that this aim must be achieved by means that do not impede the free movement of safe medicinal products within the Union.

Read More Favorite

Guideline for Good Clinical Practice E6(R2)  

Medicines | European Union

Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with GCP and the applicable regulatory requirement(s).

Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible.

Read More Favorite

Guideline on Clinical Development of Fixed Combination Medicinal Products  

Medicines | European Union

This document provides guidance on the clinical development strategy for a fixed combination medicinal product. The guidance applies primarily to small molecules irrespective of the route of administration and dosage form (immediate versus modified release), but the general principles also apply to biological products. The scientific principles are also applicable to a substance designed to dissociate in vivo into two or more active substances that form its principal therapeutic moieties. The guideline does not apply to a single molecule active substance that affects multiple pharmacological targets (i.e. has an affinity to multiple receptors involved in the desired therapeutic outcome).

Read More Favorite

Guideline on Manufacture of the Finished Dosage Form  

MedicinesHerbal Cosmetic NutraBiologicals | European Union

This guideline is applicable to the manufacture of the finished dosage form of chemical and herbal medicinal products for human use intended for marketing authorisation. It also applies to variations for authorised products in cases where changes to the manufacturing process affecting the MA are proposed.

The principles described are in general also applicable to biological medicinal products. Where relevant, the principles of this guideline may also be applied to radiopharmaceuticals and to chemical investigational medicinal products.

Read More Favorite

Excipients in the Label and Package Leaflet of Medicinal Products for Human Use  

Medicines | European Union

This guideline is for use by competent authorities, applicants for a Marketing Authorisation and Marketing Authorisation Holders. The Annex provides a list of the excipients which should be stated on the labelling and outlines the information which should appear in the package leaflet, for these excipients. This guideline does not apply to these substances when they are used as active substances.

Read More Favorite

Standard Operating Procedure for Co-ordination of Pre-Approval Inspections in the Context of Plasma Master File Certification  

Medicines | European Union

This SOP describes the process for co-ordinating pre-approval inspections of the blood establishments in which collection, testing, processing, look back, storage and distribution is carried out under the Plasma Master File (PMF) certification system. These inspections are coordinated by the P-CI-MQC section.

Read More Favorite

Guide to Reporting and Initial Investigation of Quality Defects in Medicinal Products for Human and Veterinary Use – Ireland  Recently Updated

Medicines | Ireland

A quality defect in a medicinal product may be defined as an attribute of a medicinal product or component which may affect the quality, safety and/or efficacy of the product, and/or which is not in line with the approved product authorisation (PA) or veterinary product authorisation (VPA) file, or other marketing authorisation. Reports of quality defects are received from a number of sources, such as manufacturers, pharmacists and members of the public. Certain stakeholders are required to report quality defects to the HPRA.

Quality defect report form has been attached.

Read More Favorite